Aide memoire
March 2026

Stockholm, 25 March 2026. Sobi (NASDAQ: SOBI) has compiled the following items and prior disclosures for consideration to assist in the financial modelling of the Company's Q1 2026 results.
Sobi Q4 2025 communications can be found on sobi.com/investors.

Business Items

Overall Q4 2025 revenue performance and general comments

Total revenue for Q4 2025 was SEK 7,821 M and increased by 16 per cent at CER. Strong growth from Altuvoct, Doptelet and Gamifant was partially offset by lower sales for Elocta and lower royalty on Beyfortus. Full year revenue was SEK 28,238 M and increased by 15 per cent at CER.

During Q1 2026 Sobi completed the acquisition of Arthrosi Therapeutics, strengthening pipeline for the potential treatment of gout.

Please note the following previously communicated product performances (growth at CER):

Haematology

- **Elocta and Altuvoct**: Altuvoct sales were SEK 1,023 M in Q4 2025, following strong launches and initial sales in more than 23 countries. Elocta sales were SEK 884 M in the quarter and decreased by 19 per cent at CER. Sales of Elocta in the quarter were negatively impacted by the switch of patients to Altuvoct in launched markets. The combined haemophilia A sales increased 39 per cent at CER in the quarter.
- **Alprolix:** sales were SEK 558 M in Q4 2025 and decreased by 7 per cent at CER. The decrease in the quarter was driven mainly by phasing in the international region.
- **Doptelet:** revenue was SEK 1,508 M in Q4 2025 and increased by 47 per cent at CER. The strong performance was driven by increased uptake across markets.
- **Aspaveli/Empaveli:** sales were SEK 264 M in Q4 2025 and increased by 5 per cent at CER, reflecting continued growth in number of patients across most markets, partially offset by negative impact in Europe due to increased competition.
- **Vonjo:** sales were SEK 327 M in the Q4 2025 and decreased by 10 per cent at CER. Increase in demand was outweighed by negative gross-to-net adjustments.
- **Zynlonta:** sales were SEK 44 M in Q4 2025.

Immunology

- **Kineret:** sales were SEK 741 M in Q4 2025 and increased by 6 per cent at CER, driven by increased demand across regions.
- **Gamifant**: sales were SEK 763 M in Q4 2025 and increased by 70 per cent at CER, driven by an increase in the number of patients on treatment, positive patient mix and new patients treated for MAS in Still's disease in the US.
- **Beyfortus:** Royalty earned from Sanofi's sales of Beyfortus in the US was SEK 849 M in Q4 2025.

Specialty care

Specialty Care revenue was SEK 341 M in Q4 2025 and decreased by 5 per cent at CER.

Financials

OPEX

- Selling and administrative expenses were SEK 2,964 M (3,190) in Q4 2025 (Q4 2024), including amortisation of SEK 716 M (910). IAC amounted to SEK -34 M (—). Excluding these costs and amortisation, the selling and administrative expenses increased by 6 per cent at CER.
- R&D expenses were SEK 879 M (981) in Q4 2025 (Q4 2024).

Estimated currency impact

- Based on the evolution of foreign currencies, the preliminary estimate is a negative impact on Sobi's Q1 2026 revenue of between 10% and 12% compared to constant exchange rates.

Tax rate

- Income tax was SEK -309 M (-47) in the quarter corresponding to an effective tax rate (ETR) of 14.2 per cent (3.2) in the quarter. The full year included one-off effects related to impairment of Vonjo in the third quarter and capitalisation of R&D and Orphan Drug tax credits in the fourth quarter. The quarter and full year ETR excluding one-off effects was 20.1 per cent.

Number of Shares

- Average number of ordinary shares after dilution (excluding treasury shares) was 348,652,454 in Q4 2025.

Outlook 2026

- Revenue anticipated to grow by a low double-digit percentage at CER.
- Adjusted EBITA margin is anticipated to be in the mid-30s per cent of revenue.

Forward-looking statements

This document contains certain forward-looking statements with respect to certain of the Company's current expectations and projections about future events. These statements, which sometimes use words such as "intend," "proposed," "plan," "expect," and words of similar meaning, reflect management's beliefs and expectations and involve a number of risks, uncertainties and assumptions that could cause actual results and performance to differ materially from any expected future results or performance expressed or implied by the forward-looking statement. Statements contained in this presentation regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. The information contained in this presentation is subject to change without notice and, except as required by applicable law, the Company does not assume any responsibility or obligation to update publicly or review any of the forward-looking statements contained in it. You should not place undue reliance on forward-looking statements, which speak only as at the date of this presentation.

Sobi®
Sobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. Sobi has approximately 1,900 employees across Europe, North America, the Middle East, Asia and Australia. In 2025, revenue amounted to SEK 28 billion. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com and LinkedIn.

Contacts
For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here.

Gerard Tobin
Head of Investor Relations